Janney Montgomery Scott LLC Decreases Stake in Medpace Holdings, Inc. $MEDP

Janney Montgomery Scott LLC cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 31,368 shares of the company’s stock after selling 1,150 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Medpace were worth $15,063,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of MEDP. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. acquired a new position in Medpace during the fourth quarter worth $30,000. Elyxium Wealth LLC purchased a new stake in Medpace in the 4th quarter valued at $30,000. Quarry LP acquired a new stake in shares of Medpace in the 3rd quarter worth $35,000. Finally, Bayban purchased a new position in shares of Medpace during the 4th quarter worth $44,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

NASDAQ MEDP opened at $543.57 on Thursday. The company has a market cap of $15.52 billion, a P/E ratio of 34.17, a P/E/G ratio of 2.69 and a beta of 1.15. The stock has a 50-day moving average of $452.04 and a two-hundred day moving average of $496.20. Medpace Holdings, Inc. has a 1-year low of $306.70 and a 1-year high of $628.92.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business’s quarterly revenue was up 26.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on MEDP shares. Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Barclays reduced their target price on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. BMO Capital Markets reduced their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Robert W. Baird decreased their price objective on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $467.08.

Insider Activity at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.50% of the stock is currently owned by company insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.